Education
About Us
Working with TipRanks
Follow Us
Clearside Biomedical (CLSD)
NASDAQ:CLSD
CLSD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.77 - $1.65
Previous CloseN/A
Volume106.43K
Average Volume (3M)223.20K
Market Cap
$70.81M
Enterprise Value$104.51M
Total Cash (Recent Filing)$525.00K
Total Debt (Recent Filing)$268.00K
Price to Earnings (P/E)―
Beta1.89
Next Earnings
May 08, 2025EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding77,143,875
10 Day Avg. Volume189,404
30 Day Avg. Volume223,200
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.90
Price to Cash Flow (P/CF)-3.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.48
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.70
Forecast
1Y Price Target
$5.80Price Target Upside537.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Bulls Say, Bears Say
Bulls Say
Competitive AdvantageCLS-AX offers flexible maintenance dosing every 3 to 6 months, which could be an improvement over current therapies.
FDA ApprovalFDA has approved the proposed phase 3 program for CLS-AX in wAMD.
Trial ResultsThe Phase 2b ODYSSEY trial of CLS-AX in wet AMD reported positive topline results.
Bears Say
Financial RunwayThe cash available at the end of 2024 provides a financial runway only into the fourth quarter of the following year.
Funding NeedsThe company needs to raise capital to fund the Phase 3 program.
Investment RequirementsEach phase 3 trial is expected to require a significant investment of $55MM-$60MM and take 2-3 years to report results.
---
Ownership Overview
1.83% Insiders
4.93% Mutual Funds
4.12% Other Institutional Investors
85.27% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CLSD FAQ
What was Clearside Biomedical’s price range in the past 12 months?
Clearside Biomedical lowest stock price was $0.77 and its highest was $1.65 in the past 12 months.
What is Clearside Biomedical’s market cap?
Clearside Biomedical’s market cap is $70.81M.
When is Clearside Biomedical’s upcoming earnings report date?
Clearside Biomedical’s upcoming earnings report date is May 08, 2025 which is in 36 days.
How were Clearside Biomedical’s earnings last quarter?
Clearside Biomedical released its earnings results on Mar 27, 2025. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.098 by -$0.002.
Is Clearside Biomedical overvalued?
According to Wall Street analysts Clearside Biomedical’s price is currently Undervalued.
Does Clearside Biomedical pay dividends?
Clearside Biomedical does not currently pay dividends.
What is Clearside Biomedical’s EPS estimate?
Clearside Biomedical’s EPS estimate is -0.11.
How many shares outstanding does Clearside Biomedical have?
Clearside Biomedical has 77,143,875 shares outstanding.
What happened to Clearside Biomedical’s price movement after its last earnings report?
Clearside Biomedical reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.098. Following the earnings report the stock price went down -7.767%.
Which hedge fund is a major shareholder of Clearside Biomedical?
Currently, no hedge funds are holding shares in CLSD
---
Clearside Biomedical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.80 (537.36% Upside)
$5.80 (537.36% Upside)
Insider Transactions
Bought Shares
Worth $13.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.06%
12-Months-Change
Fundamentals
Return on Equity
91.63%
Trailing 12-Months
Asset Growth
-26.14%
Trailing 12-Months
Company Description
Clearside Biomedical
Clearside Biomedical, Inc. (CLSD) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of serious back-of-the-eye diseases. The company's proprietary SCS Microinjector is designed to deliver drugs to the suprachoroidal space, offering a targeted and compartmentalized approach to treating retinal diseases such as uveitis, macular edema, and diabetic retinopathy. Clearside leverages this technology to develop a robust pipeline of product candidates, aiming to address unmet needs in ophthalmic care.
---
CLSD Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials and regulatory approvals, particularly in the Asia-Pacific region. However, the company faces challenges in securing funding for its Phase 3 program, which is crucial for its future success. The sentiment is positive due to the strong trial results and strategic partnerships, despite the funding and enrollment challenges.Read More>---
CLSD Stock 12 Month Forecast
Average Price Target
$5.80
▲(537.36% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Madrigal Pharmaceuticals
―
Aldeyra Therapeutics
―
Ocular Therapeutix
―
Kala Pharmaceuticals
―
Best Analysts Covering CLSD
1 Year
1 Year Success Rate
7/15 ratings generated profit
1 Year Average Return
+0.27%
reiterated a buy rating 6 days ago
Copying Yi Chen's trades and holding each position for 1 Year would result in 46.67% of your transactions generating a profit, with an average return of +0.27% per trade.
---